Leaflet replacement for aortic stenosis using the 3f stentless aortic bioprosthesis: midterm results

Area of Science:

• Cardiovascular Surgery
• Biomaterials Science

Background:

• The 3f aortic bioprosthesis is a novel stentless valve designed to mimic the native aortic valve.
• Its design aims for improved hemodynamic performance and potentially superior durability compared to traditional valves.

Purpose of the Study:

• To evaluate the midterm clinical outcomes and hemodynamic performance of the 3f aortic bioprosthesis.
• To assess the durability and safety of this valve substitute in patients with severe aortic stenosis.

Main Methods:

• Fifty patients with severe aortic stenosis received the 3f aortic bioprosthesis between 2002 and 2004.
• Clinical outcomes, effective orifice area, mean gradients, and ejection fraction were monitored post-implantation and during follow-up.

Main Results:

• Midterm follow-up (mean 52 months) revealed satisfactory hemodynamics for 25-mm and 27-mm valves, but smaller sizes (21-mm, 23-mm) showed higher gradients, hindering left ventricular hypertrophy regression.
• Four-year survival was 77% ± 3%, with 10 late deaths. Reoperation was required in 4 patients (endocarditis, paravalvular leak), yielding 93% freedom from reoperation at 4 years.
• Nine neurologic events occurred in 6 patients, resulting in 82% freedom from neurologic events.

Conclusions:

• The 3f aortic bioprosthesis offers simpler implantation due to its single-suture line design.
• However, its hemodynamic performance is inconsistent with established stentless valves, particularly in smaller sizes.
• A higher incidence of neurologic complications was observed during follow-up, warranting further investigation.